Memphis filmmaker Craig Brewer's new movie, "Song Sung Blue," opens in theaters in Memphis and across the U.S. and Canada on Christmas Day. Here's some information that might be helpful or interesting ...

The FDA has approved the CD19+ B-cell targeted therapy inebilizumab-cdon (Uplizna, Amgen) for the treatment of adults with generalized myasthenia gravis (gMG) who test positive for anti-acetylcholine ...

The FDA expanded the indication of inebilizumab (Uplizna) to include generalized myasthenia gravis (gMG), Amgen announced Friday. The drug is now approved to treat gMG in adults who are ...

Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new indication for its monoclonal antibody Uplizna. Thursday, the FDA greenlighted ...

In the overall population, inebilizumab demonstrated a statistically significant improvement in MG-ADL total score compared with placebo. The Food and Drug Administration (FDA) has approved Uplizna ® ...

MG Lexicon will help patients and medical professionals communicate and share common information concerning the rare autoimmune, neuromuscular disease myasthenia gravis BOSTON, Dec. 5, 2025 ...

Cynthia Erivo and Ariana Grande are back as Elphaba and Glinda for “Wicked: For Good,” Jon M. Chu’s latest film which adapts the second act of Stephen Schwartz and Winnie Holzman’s hit musical. Though ...

SAN FRANCISCO — Efgartigimod (Vyvgart), a neonatal Fc receptor (FcRn) antagonist, significantly improved symptoms in patients with anti-acetylcholine receptor antibody (AChR-Ab)-negative generalized ...

Albert Stowell's family thought he was having a stroke. It was Easter dinner 2014, and they were all gathered around the table when he started slurring his words. A trip to the emergency room and a CT ...

Treatment with cemdisiran was associated with a statistically significant improvement in MG-ADL total score compared with placebo. Topline results were announced from a phase 3 trial evaluating ...

Adam Taylor does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their ...

Regeneron Pharmaceuticals (NASDAQ:REGN) announced on Tuesday that a Phase 3 trial for its RNA-based therapy cemdisiran, developed with Alnylam Pharmaceuticals (NASDAQ:ALNY), succeeded in a late-stage ...